ASCO 2013 - Poster: Randomized double-blind, comparative study of abiraterone acetate plus low-dose prednisone plus androgen deprivation therapy (ADT) vs ADT alone in newly diagnosed, high-risk, metastatic hormone-naïve prostate cancer

CHICAGO, IL USA ( - Presented by Karim Fizazi,1 Julie S. Larsen,2 Shannon Matheny,2 Arturo Molina,2 Jinhui Li,3 Mary Todd,4 Margaret Yu,2 Thian Kheoh,2 and NamPhuong Tran2 at the American Society of Clinical Oncology (ASCO) Annual Meeting - May 31 - June 4, 2013 - McCormick Place - Chicago, IL USA

asco 2013 5097 fizazi poster thumb

1Institut Gustave Roussy, University of Paris Sud, Villejuif, France; 2Janssen Research & Development, Los Angeles, CA; 3Janssen Research & Development, Raritan, NJ; 4Janssen Global Services, Raritan, NJ


The ASCO Annual Meeting brings together more than 25,000 oncology professionals from a broad range of specialties, making it an excellent venue for exploring the theme of the Meeting — "Building Bridges to Conquer Cancer."

asco x

View Full ASCO 2013 Coverage